Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Net Cash Flow (2020 - 2025)

Cytek Biosciences' Net Cash Flow history spans 6 years, with the latest figure at -$3.8 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 94.1% year-over-year to -$3.8 million; the TTM value through Dec 2025 reached -$8.0 million, up 89.1%, while the annual FY2025 figure was -$8.0 million, 89.1% up from the prior year.
  • Net Cash Flow reached -$3.8 million in Q4 2025 per CTKB's latest filing, down from $17.0 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $216.9 million in Q3 2021 to a low of -$166.0 million in Q1 2023.
  • Average Net Cash Flow over 5 years is -$3.9 million, with a median of -$3.0 million recorded in 2025.
  • Peak YoY movement for Net Cash Flow: surged 43113.35% in 2021, then tumbled 8656.12% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at -$12.8 million in 2021, then plummeted by 219.7% to -$41.0 million in 2022, then soared by 111.76% to $4.8 million in 2023, then plummeted by 1449.0% to -$65.1 million in 2024, then soared by 94.1% to -$3.8 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Net Cash Flow are -$3.8 million (Q4 2025), $17.0 million (Q3 2025), and -$18.9 million (Q2 2025).